Actelion faces US sales probe over Tracleer
This article was originally published in Scrip
The Swiss firm Actelion said that its US subsidiary has received a subpoena from the US Attorney's Office for the Northern District of California requesting documents relating to marketing and sales practices of Tracleer (bosentan) in the US. Tracleer is a prescription medication for the treatment of patients with pulmonary arterial hypertension. The company added that it intends to "cooperate with the investigation".